197 related articles for article (PubMed ID: 30679645)
1. Attenuation of murine sclerodermatous models by the selective S1P
Kano M; Kobayashi T; Date M; Tennichi M; Hamaguchi Y; Strasser DS; Takehara K; Matsushita T
Sci Rep; 2019 Jan; 9(1):658. PubMed ID: 30679645
[TBL] [Abstract][Full Text] [Related]
2. Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease.
Matsushita T; Date M; Kano M; Mizumaki K; Tennichi M; Kobayashi T; Hamaguchi Y; Hasegawa M; Fujimoto M; Takehara K
Am J Pathol; 2017 Apr; 187(4):841-850. PubMed ID: 28189565
[TBL] [Abstract][Full Text] [Related]
3. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
Huu DL; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
Arthritis Rheum; 2013 Jun; 65(6):1624-35. PubMed ID: 23508350
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Characterization of Sphingosine 1-Phosphate Receptor 1 (S1P
Schlicher L; Kulig P; von Münchow A; Murphy MJ; Keller MP
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163112
[TBL] [Abstract][Full Text] [Related]
5. Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model.
Hasegawa T; Utsunomiya A; Chino T; Kasamatsu H; Shimizu T; Matsushita T; Obara T; Ishii N; Ogasawara H; Ikeda W; Imai T; Oyama N; Hasegawa M
Arthritis Res Ther; 2024 May; 26(1):94. PubMed ID: 38702742
[TBL] [Abstract][Full Text] [Related]
6. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
7. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Tedder TF; Fujimoto M
Blood; 2013 Apr; 121(16):3274-83. PubMed ID: 23422748
[TBL] [Abstract][Full Text] [Related]
8. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.
Zhang Y; McCormick LL; Desai SR; Wu C; Gilliam AC
J Immunol; 2002 Mar; 168(6):3088-98. PubMed ID: 11884483
[TBL] [Abstract][Full Text] [Related]
9. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
J Invest Dermatol; 2012 Dec; 132(12):2752-61. PubMed ID: 22810302
[TBL] [Abstract][Full Text] [Related]
10. Combination of 5-aminolevulinic acid and iron prevents skin fibrosis in murine sclerodermatous graft-versus-host disease.
Liu C; Yang X; Zhu P; Fujino M; Ito H; Takahashi K; Nakajima M; Tanaka T; Wang J; Zhuang J; Zou H; Li XK
Exp Dermatol; 2018 Oct; 27(10):1104-1111. PubMed ID: 29978518
[TBL] [Abstract][Full Text] [Related]
11. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
Zhang Y; McCormick LL; Gilliam AC
J Invest Dermatol; 2003 Oct; 121(4):713-9. PubMed ID: 14632186
[TBL] [Abstract][Full Text] [Related]
12. Adipose-derived stromal/stem cells successfully attenuate the fibrosis of scleroderma mouse models.
Okamura A; Matsushita T; Komuro A; Kobayashi T; Maeda S; Hamaguchi Y; Takehara K
Int J Rheum Dis; 2020 Feb; 23(2):216-225. PubMed ID: 31808305
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
[TBL] [Abstract][Full Text] [Related]
14. Preclinical to clinical translation of cenerimod, a novel S1P
Strasser DS; Froidevaux S; Sippel V; Gerossier E; Grieder U; Pierlot GM; Kieninger-Graefitsch A; Vezzali E; Stalder AK; Renault B; Ryge J; Hart A; Mentzel U; Groenen PMA; Keller MP; Trendelenburg M; Martinic MM; Murphy MJ
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32917831
[TBL] [Abstract][Full Text] [Related]
15. Cenerimod, a selective S1P
Gerossier E; Nayar S; Froidevaux S; Smith CG; Runser C; Iannizzotto V; Vezzali E; Pierlot G; Mentzel U; Murphy MJ; Martinic MM; Barone F
Arthritis Res Ther; 2021 Nov; 23(1):289. PubMed ID: 34839819
[TBL] [Abstract][Full Text] [Related]
16. Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P
Boof ML; van Lier JJ; English S; Fischer H; Ufer M; Dingemanse J
Xenobiotica; 2020 Aug; 50(8):947-956. PubMed ID: 32105166
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T
J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905
[TBL] [Abstract][Full Text] [Related]
18. CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.
Lim JY; Ryu DB; Kim TW; Lee SE; Park G; Yoon HK; Min CK
Stem Cell Res Ther; 2020 Jun; 11(1):254. PubMed ID: 32586381
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
20. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.
McCormick LL; Zhang Y; Tootell E; Gilliam AC
J Immunol; 1999 Nov; 163(10):5693-9. PubMed ID: 10553100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
